Universe Common Stock Total Equity vs Accounts Payable Analysis

UPC Stock

USD 2.51 0.07 2.71%

Universe Pharmaceuticals financial indicator trend analysis is much more than just breaking down Universe Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Universe Pharmaceuticals is a good investment. Please check the relationship between Universe Pharmaceuticals Common Stock Total Equity and its Accounts Payable accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.

Common Stock Total Equity vs Accounts Payable

Common Stock Total Equity vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Universe Pharmaceuticals Common Stock Total Equity account and Accounts Payable. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Universe Pharmaceuticals' Common Stock Total Equity and Accounts Payable is -0.37. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Universe Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Universe Pharmaceuticals' Common Stock Total Equity and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Universe Pharmaceuticals are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Common Stock Total Equity i.e., Universe Pharmaceuticals' Common Stock Total Equity and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.37

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Accounts Payable

An accounting item on the balance sheet that represents Universe Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Universe Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Universe Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Universe Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.As of May 17, 2024, Tax Provision is expected to decline to about 1.6 M. In addition to that, Selling General Administrative is expected to decline to about 1.8 M

	2021	2022	2023	2024 (projected)
Interest Expense	162.4K	156.8K	180.3K	153.8K
Depreciation And Amortization	621.5K	508.8K	457.9K	427.6K

Interest Expense Depreciation And Amortization

Universe Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Long Term Investments	Property Plant And Equipment Gross	Short Long Term Debt
Total Assets		0.85	-0.56	-0.2	0.97	0.97	0.96	-0.34	0.42	0.83	0.88	0.21	0.98	0.93	0.98	0.93	-0.34	-0.65	-0.62	0.68	0.96	-0.2	0.97	-0.4	0.91	0.85
Short Long Term Debt Total	0.85		-0.59	-0.18	0.83	0.89	0.95	-0.44	0.65	0.59	0.88	-0.02	0.9	0.88	0.9	0.68	-0.44	-0.67	-0.6	0.33	0.93	-0.18	0.85	-0.61	0.96	1.0
Other Current Liab	-0.56	-0.59		0.89	-0.73	-0.73	-0.61	0.35	-0.38	-0.8	-0.44	-0.1	-0.62	-0.66	-0.64	-0.64	0.35	0.97	0.97	-0.46	-0.63	0.89	-0.73	0.45	-0.58	-0.59
Total Current Liabilities	-0.2	-0.18	0.89		-0.43	-0.4	-0.24	0.12	-0.12	-0.62	-0.01	-0.07	-0.27	-0.31	-0.29	-0.39	0.12	0.84	0.86	-0.31	-0.28	1.0	-0.42	0.19	-0.21	-0.18
Total Stockholder Equity	0.97	0.83	-0.73	-0.43		0.99	0.95	-0.34	0.42	0.92	0.81	0.21	0.97	0.94	0.98	0.95	-0.34	-0.81	-0.78	0.7	0.96	-0.43	1.0	-0.42	0.89	0.83
Net Tangible Assets	0.97	0.89	-0.73	-0.4	0.99		0.97	-0.33	0.46	0.88	0.85	0.17	0.98	0.94	0.99	0.92	-0.33	-0.8	-0.77	0.65	0.98	-0.4	1.0	-0.43	0.93	0.89
Property Plant And Equipment Net	0.96	0.95	-0.61	-0.24	0.95	0.97		-0.38	0.6	0.75	0.89	0.03	0.99	0.95	0.97	0.84	-0.38	-0.71	-0.65	0.54	1.0	-0.24	0.96	-0.51	0.98	0.95
Current Deferred Revenue	-0.34	-0.44	0.35	0.12	-0.34	-0.33	-0.38		-0.55	-0.28	-0.37	-0.11	-0.36	-0.59	-0.36	-0.33	1.0	0.36	0.36	0.04	-0.36	0.12	-0.35	0.94	-0.38	-0.44
Net Debt	0.42	0.65	-0.38	-0.12	0.42	0.46	0.6	-0.55		0.14	0.4	-0.65	0.55	0.64	0.42	0.22	-0.55	-0.42	-0.35	-0.06	0.59	-0.12	0.44	-0.76	0.65	0.65
Retained Earnings	0.83	0.59	-0.8	-0.62	0.92	0.88	0.75	-0.28	0.14		0.64	0.42	0.81	0.79	0.85	0.94	-0.28	-0.83	-0.84	0.79	0.77	-0.62	0.91	-0.26	0.65	0.59
Accounts Payable	0.88	0.88	-0.44	-0.01	0.81	0.85	0.89	-0.37	0.4	0.64		0.23	0.85	0.81	0.87	0.7	-0.37	-0.47	-0.41	0.62	0.84	-0.01	0.83	-0.4	0.81	0.88
Cash	0.21	-0.02	-0.1	-0.07	0.21	0.17	0.03	-0.11	-0.65	0.42	0.23		0.06	0.08	0.25	0.4	-0.11	-0.1	-0.17	0.34	0.02	-0.07	0.2	0.12	-0.05	-0.02
Non Current Assets Total	0.98	0.9	-0.62	-0.27	0.97	0.98	0.99	-0.36	0.55	0.81	0.85	0.06		0.96	0.98	0.89	-0.36	-0.72	-0.67	0.61	0.99	-0.27	0.98	-0.47	0.95	0.9
Other Assets	0.93	0.88	-0.66	-0.31	0.94	0.94	0.95	-0.59	0.64	0.79	0.81	0.08	0.96		0.94	0.87	-0.59	-0.75	-0.71	0.5	0.95	-0.31	0.94	-0.67	0.92	0.88
Cash And Short Term Investments	0.98	0.9	-0.64	-0.29	0.98	0.99	0.97	-0.36	0.42	0.85	0.87	0.25	0.98	0.94		0.93	-0.36	-0.74	-0.71	0.61	0.97	-0.29	0.98	-0.45	0.94	0.9
Net Receivables	0.93	0.68	-0.64	-0.39	0.95	0.92	0.84	-0.33	0.22	0.94	0.7	0.4	0.89	0.87	0.93		-0.33	-0.73	-0.75	0.7	0.86	-0.39	0.94	-0.34	0.78	0.68
Common Stock Total Equity	-0.34	-0.44	0.35	0.12	-0.34	-0.33	-0.38	1.0	-0.55	-0.28	-0.37	-0.11	-0.36	-0.59	-0.36	-0.33		0.36	0.36	0.04	-0.36	0.12	-0.35	0.94	-0.38	-0.44
Common Stock Shares Outstanding	-0.65	-0.67	0.97	0.84	-0.81	-0.8	-0.71	0.36	-0.42	-0.83	-0.47	-0.1	-0.72	-0.75	-0.74	-0.73	0.36		0.99	-0.41	-0.74	0.84	-0.81	0.49	-0.7	-0.67
Inventory	-0.62	-0.6	0.97	0.86	-0.78	-0.77	-0.65	0.36	-0.35	-0.84	-0.41	-0.17	-0.67	-0.71	-0.71	-0.75	0.36	0.99		-0.42	-0.69	0.86	-0.78	0.47	-0.64	-0.6
Other Current Assets	0.68	0.33	-0.46	-0.31	0.7	0.65	0.54	0.04	-0.06	0.79	0.62	0.34	0.61	0.5	0.61	0.7	0.04	-0.41	-0.42		0.53	-0.31	0.69	0.14	0.37	0.33
Other Stockholder Equity	0.96	0.93	-0.63	-0.28	0.96	0.98	1.0	-0.36	0.59	0.77	0.84	0.02	0.99	0.95	0.97	0.86	-0.36	-0.74	-0.69	0.53		-0.28	0.96	-0.5	0.98	0.93
Total Liab	-0.2	-0.18	0.89	1.0	-0.43	-0.4	-0.24	0.12	-0.12	-0.62	-0.01	-0.07	-0.27	-0.31	-0.29	-0.39	0.12	0.84	0.86	-0.31	-0.28		-0.42	0.19	-0.21	-0.18
Net Invested Capital	0.97	0.85	-0.73	-0.42	1.0	1.0	0.96	-0.35	0.44	0.91	0.83	0.2	0.98	0.94	0.98	0.94	-0.35	-0.81	-0.78	0.69	0.96	-0.42		-0.43	0.9	0.85
Long Term Investments	-0.4	-0.61	0.45	0.19	-0.42	-0.43	-0.51	0.94	-0.76	-0.26	-0.4	0.12	-0.47	-0.67	-0.45	-0.34	0.94	0.49	0.47	0.14	-0.5	0.19	-0.43		-0.57	-0.61
Property Plant And Equipment Gross	0.91	0.96	-0.58	-0.21	0.89	0.93	0.98	-0.38	0.65	0.65	0.81	-0.05	0.95	0.92	0.94	0.78	-0.38	-0.7	-0.64	0.37	0.98	-0.21	0.9	-0.57		0.96
Short Long Term Debt	0.85	1.0	-0.59	-0.18	0.83	0.89	0.95	-0.44	0.65	0.59	0.88	-0.02	0.9	0.88	0.9	0.68	-0.44	-0.67	-0.6	0.33	0.93	-0.18	0.85	-0.61	0.96

Click cells to compare fundamentals

Universe Pharmaceuticals Account Relationship Matchups

Universe Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	28.8M	70.1M	59.5M	53.3M	61.3M	47.2M
Short Long Term Debt Total	2.6M	4.3M	3.9M	5.5M	6.3M	3.9M
Other Current Liab	2.7M	1.6M	6.1M	3.7M	3.3M	3.6M
Total Current Liabilities	8.0M	11.2M	13.1M	13.8M	15.8M	12.8M
Total Stockholder Equity	20.8M	58.9M	46.4M	39.5M	45.5M	34.4M
Net Tangible Assets	12.2M	20.6M	58.8M	46.3M	53.2M	32.4M
Property Plant And Equipment Net	4.4M	15.4M	13.6M	15.0M	17.2M	10.6M
Net Debt	(7.4M)	(3.7M)	(1.8M)	197.2K	226.8K	238.1K
Retained Earnings	13.7M	25.1M	16.3M	10.2M	11.7M	13.6M
Accounts Payable	2.7M	5.3M	3.1M	4.6M	5.3M	3.8M
Cash	10.1M	8.1M	5.7M	5.3M	6.1M	7.1M
Non Current Assets Total	5.5M	19.7M	18.0M	16.5M	18.9M	13.1M
Other Assets	168.1K	186.5K	14.1M	12.9M	14.9M	15.6M
Cash And Short Term Investments	10.1M	21.8M	18.9M	18.5M	21.3M	14.4M
Net Receivables	10.9M	15.8M	15.2M	10.7M	12.3M	12.2M
Liabilities And Stockholders Equity	28.8M	70.1M	59.5M	53.3M	61.3M	47.2M
Inventory	1.9M	2.5M	2.2M	3.3M	3.0M	2.8M
Other Current Assets	443.7K	10.4M	1.7M	626.2K	720.2K	684.2K
Total Liab	8.0M	11.2M	13.1M	13.8M	15.8M	12.8M
Net Invested Capital	23.4M	63.3M	50.4M	45.0M	51.8M	38.4M
Long Term Investments	735K	744.9K	702.9K	685.3K	616.8K	572.9K
Property Plant And Equipment Gross	4.4M	15.4M	19.3M	21.0M	24.2M	12.8M
Short Long Term Debt	2.6M	4.3M	3.9M	5.5M	6.3M	3.9M
Total Current Assets	23.3M	50.5M	41.5M	36.8M	42.3M	34.1M
Accumulated Other Comprehensive Income	3.3M	4.5M	772.8K	26.3K	23.6K	22.5K
Net Working Capital	15.3M	39.3M	28.4M	23.1M	26.5M	21.3M
Short Term Debt	2.6M	4.3M	3.9M	5.5M	6.3M	3.9M
Intangible Assets	174.8K	178.5K	157.5K	148.6K	133.7K	135.3K
Property Plant Equipment	4.6M	4.4M	4.7M	4.3M	3.8M	3.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Universe Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Universe Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Universe Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Universe Pharmaceuticals Stock:

How To Invest In Universe

Details

Is Universe Stock a good investment?

Details

What is Universe Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.

You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Universe Stock analysis

When running Universe Pharmaceuticals' price analysis, check to measure Universe Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Universe Pharmaceuticals is operating at the current time. Most of Universe Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Universe Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Universe Pharmaceuticals' price. Additionally, you may evaluate how the addition of Universe Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites

Is Universe Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Universe Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.82)

Earnings Share

(1.70)

Revenue Per Share

8.913

Quarterly Revenue Growth

(0.13)

Return On Assets

(0.04)

The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Universe Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Universe Common Stock Total Equity vs Accounts Payable Analysis

Common Stock Total Equity vs Accounts Payable

Common Stock Total Equity vs Accounts Payable Correlation Analysis

Correlation Coefficient

Common Stock Total Equity

Accounts Payable

Universe Pharmaceuticals fundamental ratios Correlations

Universe Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Universe Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Universe Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Long Term Debt	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Net Tangible Assets
Other Stockholder Equity	+ 1.0	Property Plant And Equipment Net
Common Stock Total Equity	+ 1.0	Current Deferred Revenue

Inventory	- 0.84	Retained Earnings
Common Stock Shares Outstanding	- 0.83	Retained Earnings
Net Invested Capital	- 0.81	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.81	Total Stockholder Equity
Common Stock Shares Outstanding	- 0.8	Net Tangible Assets
Retained Earnings	- 0.8	Other Current Liab